Health
Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a midstage trial. The initial study […]
Read More
Wall Street says Big Tech needs to take a breather after huge run. Here's our take
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. U.S. stocks were mixed Tuesday, on a muted performance from Big Tech. Citigroup strategists warned that tech stocks may stall out after monstrous gains. “The large consensus positioning is […]
Read More
Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue
Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. Mike Blake | Reuters Eli Lilly on Tuesday reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes drug, Mounjaro. […]
Read More
Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. Victoria Klesty | Reuters Novo Nordisk‘s parent company on Monday said it will acquire drug manufacturer Catalent in a $16.5 billion deal that could help boost the supply of the highly popular weight loss injection […]
Read More
Fourth-quarter earnings are shaping up to be the best of 2023, but there's a catch
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 1, 2024. Brendan McDermid | Reuters Here’s how big of a surprise corporate profits have been this earnings season: the fourth-quarter is now shaping up to be the best of 2023. Despite ongoing macroeconomic concerns that have […]
Read More
Here are Jim Cramer’s rapid-fire takeaways on 6 stocks in the news Friday
Clorox – The consumer products giant saw a huge earnings beat. It’s also rebounding from last year’s cyberattack. “Things are back online, and there’s tremendous demand for their product,” Jim said Friday’s Morning Meeting rapid fire. Tesla – The EV leader issued a recall for 2.2 million cars over a warning light issue. Remember, our […]
Read More
January was great for stocks — here are our top 5 performers for the month
Benchmark gauges notched all-time highs as stocks charged through a busy earnings season. Source
Read More
Bristol Myers Squibb results top estimates as new drugs post strong sales growth
Bristol Myers Squibb reported quarterly earnings and revenue that topped expectations on Friday as its portfolio of new drugs posted strong sales growth. Here’s what the company reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv: Earnings per share: $1.70 […]
Read More
Neuralink competitor Synchron to ramp up brain implant production with equity stake in manufacturer
Philip O’Keefe, one of Synchron’s patients in the SWITCH clinical trial, was the first person in the world to tweet using a BCI device. Source: Synchron Neurotech startup Synchron is ramping up production of its flagship brain-computer interface to prepare for commercial demand, as the company inches closer to bringing its device to market. Synchron […]
Read More
Merck results beat expectations as top drugs Keytruda, Gardasil post strong sales
The logo for Merck & Co. is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, New York, U.S., November 17, 2021. Andrew Kelly | Reuters Merck on Thursday reported fourth-quarter revenue and adjusted earnings that topped estimates as it saw strong demand for its blockbuster cancer drug Keytruda […]
Read More